Difference between revisions of "Sintilimab (Tyvyt)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Hodgkin lymphoma " to "[[Category:Classical Hodgkin lymphoma ") |
||
| Line 20: | Line 20: | ||
[[Category:Esophageal squamous cell carcinoma medications]] | [[Category:Esophageal squamous cell carcinoma medications]] | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
Revision as of 14:20, 9 June 2023
Mechanism of action
From NCI Drug Dictionary: A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Hodgkin lymphoma
- Non-small cell lung cancer
Also known as
- Code name: IBI 308
- Brand name: Tyvyt